Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations QGE031 - Anti-IgE Study Indication Phase NCT03580356 PEARL 2 (CQGE031C2303) Chronic spontaneous urticaria Phase 3 Patients Primary Outcome 1050 Absolute change from baseline in UAS7 (Urticaria Activity Score) at week 12 Measures Arms Intervention Ligelizumab dose A q4w for 52 weeks Ligelizumab dose B q4w for 52 weeks Target Patients Read-out Milesstone(s) Publication Omalizumab 300 mg q4w for 52 weeks Placebo q4w from randomization to wk20, then ligelizumab dose B from wk24 to wk52 Adolescents and adults with chronic spontaneous urticaria inadequately controlled with H1-antihistamines H2-2021 (Q4/2021-Q1/2022 potential COVID impact) Past publications: Study design presented at UCARE 2018 Congress: primary results EADV 2022 (H2 2022) or AAAAI 2023 Manuscript: primary results, Journal (TBD), 2023 NCT03580369 PEARL 1 (CQGE031C2302) Chronic spontaneous urticaria Phase 3 1050 Absolute change from baseline in UAS7 (Urticaria Activity Score) at week 12 Ligelizumab dose A q4w for 52 weeks Ligelizumab dose B q4w for 52 weeks Omalizumab 300 mg q4w for 52 weeks Placebo q4w from randomization to wk20, then ligelizumab dose B from wk24 to wk52 Adolescents and adults with chronic spontaneous urticaria inadequately controlled with H1-antihistamines H2-2021 (Q4/2021-Q1/2022 potential COVID impact) Past publications: Study design presented at UCARE 2018 Congress: primary results EADV 2022 (H2 2022) or AAAAI 2023 Manuscript: primary results, Journal (TBD), 2023 84 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation